Advanced search
Start date
Betweenand
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Atorvastatin administered before myocardial infarction in rats improves contractility irrespective of metabolic changes

Full text
Author(s):
Lehnen, Tatiana Ederich [1, 2, 3] ; Lehnen, Alexandre Machado [1, 2, 3] ; Vicente Tavares, Angela Maria [4] ; Bello-Klein, Adriane [4] ; Markoski, Melissa Medeiros [3] ; Machado, Ubiratan Fabres [5] ; Schaan, Beatriz [1, 2, 3]
Total Authors: 7
Affiliation:
[1] Univ Fed Rio Grande do Sul, Postgrad Program Endocrinol, Porto Alegre, RS - Brazil
[2] Hosp Clin Porto Alegre, Div Endocrine, BR-90035003 Porto Alegre, RS - Brazil
[3] Univ Fdn Cardiol Rio Grande Sul, Inst Cardiol, Porto Alegre, RS - Brazil
[4] Univ Fed Rio Grande do Sul, Inst Basic Hlth Sci, Lab Cardiovasc Physiol, Porto Alegre, RS - Brazil
[5] Univ Sao Paulo, Inst Biomed Sci, Dept Physiol & Biophys, Sao Paulo - Brazil
Total Affiliations: 5
Document type: Journal article
Source: Clinical and Experimental Pharmacology and Physiology; v. 41, n. 12, p. 986-994, DEC 2014.
Web of Science Citations: 4
Abstract

Statins have a beneficial effect after myocardial infarction, but the relationship between glucose transporters and their use before the event has not yet been studied. We assessed the effects of atorvastatin treatment pre- and post-myocardial infarction on cardiovascular function and glucose transporter 4 (GLUT4) in the heart. Wistar-Kyoto rats were treated with 20 mg/kg atorvastatin or vehicle for 14 days before coronary artery occlusion surgery (myocardial infarction) or sham surgery. Echocardiographic evaluations were carried out 48 h after myocardial infarction (protocol A) and after 7 days (protocol B), when atorvastatin was also administered. Plasma inflammatory markers and GLUT4 in the heart were also evaluated. Animals were divided into the following groups: sham-operated and vehicle (C), myocardial infarction and vehicle (I), sham-operated and atorvastatin (CAt) and myocardial infarction and atorvastatin (IAt). After 48 h, myocardial infarction induced higher left ventricular fractional shortening in IAt versus I (similar to 60%, P = 0.036), and the ejection fraction was lower (protocol A similar to 37%; protocol B similar to 30%). Myocardial infarction was associated with a rise in plasma membrane GLUT4 after 48 h (similar to 40%, P < 0.001), and a reduction in GLUT4 after 7 days (I 25%; IAt 49%, P < 0.001). Atorvastatin treatment for 48 h after the infarction did not change GLUT4 expression, and after 7 days it had an additional negative effect on GLUT4 content (similar to 39%, P = 0.030). In conclusion, atorvastatin treatment pre- and post-myocardial infarction improved myocardial contractility after 48 h, but not after 7 days, and was not associated with an increase in GLUT4 expression. (AU)

FAPESP's process: 12/04831-1 - New players in glycemic control and chronic complications of Diabetes mellitus: preventive and therapeutic perspectives
Grantee:Ubiratan Fabres Machado
Support type: Research Projects - Thematic Grants